First elected: 7th May 2015
Left House: 30th May 2024 (Dissolution)
Speeches made during Parliamentary debates are recorded in Hansard. For ease of browsing we have grouped debates into individual, departmental and legislative categories.
These initiatives were driven by Marcus Fysh, and are more likely to reflect personal policy preferences.
MPs who are act as Ministers or Shadow Ministers are generally restricted from performing Commons initiatives other than Urgent Questions.
Marcus Fysh has not been granted any Urgent Questions
Marcus Fysh has not introduced any legislation before Parliament
Roadworks (Regulation) Bill 2022-23
Sponsor - Mark Francois (Con)
Rivers Authorities and Land Drainage Bill 2017-19
Sponsor - David Warburton (Ind)
House of Commons (Precedence of Government Business) (European Union (Withdrawal) Act 2018)
Sponsor - William Cash (Con)
We are committed to tackling hate crime in any form. The cross Government Hate Crime Action Plan, published in July 2016, focuses on reducing hate crime, increasing reporting and ensuring that all criminal justice partners and key stakeholders deliver the appropriate outcomes for victims.
His Majesty’s Government operates on the principle of collective responsibility, and the Government would not normally comment on the internal processes of how advice may be determined. Ministers must be able to speak to officials and take advice from a position of absolute trust. Naming which individuals may or may not have provided advice on a particular topic may inhibit the ability of civil servants to provide free and frank advice and inhibit the free and frank exchange of views for the purposes of deliberation.
Moreover, the Civil Service Code makes clear that civil servants are accountable to Ministers who in turn are accountable to Parliament.
Notwithstanding, as Ministers set out in the response of 7 March 2023, Official Report, Columns 689, it is exceptional and unprecedented for a serving Permanent Secretary to resign to seek to take up a senior position working for the leader of the Opposition. The Cabinet Office has publicly stated it is looking into the circumstances leading up to the Second Permanent Secretary's resignation.
In that exceptional context, I believe it is appropriate to confirm to the Hon. Member that the former Second Permanent Secretary neither advised on, nor participated in, negotiations on the Windsor Framework.
The information requested falls under the remit of the UK Statistics Authority. I have therefore asked the Authority to respond.
Improving the efficiency and productivity of the public sector is central to the work of the Cabinet Office and other government Departments. By 2014/15 the Government had saved £18.6 billion through efficiency and reform.
The government is continuing this work. For example, we are working to improve how the government operates across functional areas such as commercial, property, infrastructure and projects, and by tackling fraud, error and debt. We will continue to make government more effective throughout this parliament.
Progress is being made at an extraordinary pace to secure a safe and effective vaccine. We monitor trial results on a continuous basis and the trials look to establish different things depending on how they are designed and what they specifically look at. The outcomes of the clinical trials will not be fully known until phase 3 trials have concluded.
The Government is working at pace to secure a safe and effective vaccine for all. To date, we have secured 350 million doses through six different vaccine developers.
The National Institute for Health Research (NIHR) and UK Research and Innovation (UKRI) are helping to fund and/or deliver a range of 'rapid response' research to better understand and tackle COVID-19, including research into vaccines, treatments and diagnostic tests. The government has also invested over £230 million in manufacturing facilities, to manufacture a vaccine quickly, if and when a candidate becomes successful. Manufacturers and wholesalers of COVID-19 vaccine candidates must meet the Medicines and Healthcare products Regulatory Agency’s (MHRA) standards of good manufacturing practice (GMP) and good distribution practice (GDP). MHRA carries out inspections to check if manufacturing and distribution sites comply with GMP or GDP.
The National Institute for Health Research provides support and critical infrastructure for clinical trials – making the UK well-suited to facilitate clinical trials that are essential to the development of any vaccine.
All vaccines are tested through three phases of clinical trials, to ensure they meet the usual rigorous standards, data must include the results of clinical trials, animal studies, manufacturing and in-process quality controls, consistency in batches production, and testing data. Clinical trials of any vaccine must follow a predefined development pathway, with regulatory oversight provided by the Medicines and Healthcare Products Regulatory Agency (MHRA). The MHRA will seek advice from the independent expert advisors on the Commission on Human Medicines and its Expert Advisory Group on the risks and benefits of any vaccine. A vaccine will only be deployed once it has been proved to be safe and effective.
Schools play a very important part in identifying pupils who are young carers and in offering them appropriate support.
During school inspection, Ofsted inspectors consider how schools are meeting the needs of their pupils, including young carers. It is for schools to demonstrate to inspectors that they know all of their pupils, including those with caring responsibilities, and have strategies in place to support these pupils and ensure that they are making expected progress.
This Department has funded the Carers Trust and The Children’s Society, in partnership with Suffolk Family Carers, to work with local authorities to develop models of assessment and support that specifically address the needs of young carers. We have also trained school nurses to be champions for young carers, to speak up on behalf of young carers and help head teachers and governors decide how best to support them at school.
The UK is fully committed to upholding the global moratorium on Commercial Whaling adopted by the International Whaling Commission in 1986. The moratorium is enforced by the appropriate authorities. We are not aware of any illegal whaling activity that takes place in British-administered waters.
Farmers and other land managers make a vital contribution to supporting pollinators through management and creation of beneficial habitat features. This is reflected in Defra’s National Pollinator Strategy implementation plan.
Well over one thousand applications for the new Countryside Stewardship Scheme, which funds environmentally beneficial land management, contained the Wild Pollinator and Farm Wildlife Package. As part of our monitoring and evaluation programme, we will assess the effectiveness of the Scheme in supporting bees and other pollinators.
Following intense negotiations on the Northern Ireland Protocol in the preceding weeks and months, the Draft Agreement on the withdrawal of the United Kingdom of Great Britain and Northern Ireland from the European Union and the European Atomic Energy Community, including all of the annexes in question, was published on 14 November and the final version was agreed at a special European Council on 25 November 2018.
DFID’s SME Action Plan sets out a range of measures to promote access. These include increased use of social media, a specific email address and forums for SMEs, and breaking up suitable contracts into smaller lots for delivery by SMEs.
Highways England is currently designing safety schemes to improve safety at both roundabouts at either end of the Ilminster By-pass. The Road Investment Strategy also announced, in addition to the schemes on the A303 to be taken forward in the period up to 2020/21, the Government’s intention to up-grade the A303 in subsequent road investment periods, post-2020, which will include the up-grade of the Ilminster By-pass to a dual carriageway, which will aim to further improve safety.
I do however offer my deepest sympathies to the families and friends of the people who lost their lives or were seriously injured in the collisions on the Ilminster By-pass in July 2015.
These collisions are still under Police investigation and until concluded it would be inappropriate to speculate on causes and subsequent improvements to that stretch of road. It is important to base decisions on evidence and Highways England will work with partner agencies to further reduce casualties on our roads in light of the evidence as it emerges.
We are investing significant resources in this area including increasing the coverage of the Talking Therapy services by 600,000 people per year to 1.5million by 2020. We are also investing in trials and initiatives with a view to taking forward those that work best for individuals.
Mental Health is a key feature of our Green Paper Improving Lives published on 31 October 2016.
The focus in March 2020 was on the required National Health Service capacity to respond to the first wave of COVID-19 cases, rather than a potential second wave.
Guidance issued by the NHS in March had set out an operational aim to expand critical care capacity to the maximum and free up 30,000 or more general and acute beds.
Our mass testing pilot in Liverpool continues and will help inform any future rollout of large-scale population testing. We are now rolling out this localised approach to other areas. Eighty three local authorities have now signed up to receive regular batches of these new lateral flow tests, which can allow for results in minutes.
Individual modelling groups use a range of data to estimate growth rates and ‘R’ values, including:
- epidemiological data such as testing data, hospital admissions, intensive care unit admissions and deaths;
- contact pattern surveys that gather information on behaviour; and
- household infection surveys where swabs are performed on individuals.
Different modelling groups use different data sources to estimate these values using mathematical models that simulate the spread of infections. Some may even use all these sources of information to adjust their models to better reflect the real-world situation. Estimates can vary between different models, so evidence from several models is considered, discussed, combined and the growth rate and ‘R’ is then presented as ranges.
Rounding and differences between the data streams used in these individual model outputs that are combined account for differences between estimates of ‘R’ and estimated growth rates. The Scientific Advisory Group for Emergencies calculates ‘R’ at United Kingdom, devolved administration and at NHS England regional levels. It does not produce estimates for local authority areas.
Based on data from 15 March 2020 to week ending 1 November 2020 submitted to Public Health England’s Severe Acute Respiratory Infection-Watch, 30% of new admissions for acute respiratory infection (ARI) to any ward, including intensive care units, (ICU) and high dependency units (HDU), in hospitals in England had a laboratory confirmed COVID-19 test.
Over the same time period, 42% of new admissions to ICU/HDU for ARI had a laboratory confirmed COVID-19 test.
Further information on ICU/HDU admission rates by region and by trust in the weekly surveillance reports is available at the following link:
https://www.gov.uk/government/statistics/national-flu-and-covid-19-surveillance-reports
Decisions on tiers are made by Ministers based on public health recommendations from senior clinical and scientific advisors, guided by five key indicators - the case detection rate in all age groups, case detection rates among the over 60 year olds, the rate at which case rates are rising or falling, positivity rate and pressures on the National Health Service. Final decisions on tiering are made by the COVID-19 Operations Committee.
As of 6 January, all areas have moved into tier 4 and the Government will review the tiering allocations every 14 days.
There is broad agreement between international regulators on both the safety and the efficacy criteria that would be required for approval and authorisation of a COVID-19 vaccine. These criteria will apply to all COVID-19 vaccine candidates, irrespective of whether they receive funding from the United Kingdom Government.
The Medicines and Healthcare products Regulatory Agency (MHRA) will perform the assessment of the quality, safety and efficacy data submitted by developers of COVID-19 vaccines and will seek the advice of its independent expert advisors on the Commission on Human Medicines.
No approval will be given for any COVID-19 vaccine without robust evidence of efficacy and safety. The MHRA has teams of assessors available to review the submissions.
To expedite the review of COVID-19 vaccine applications, developers of COVID-19 vaccines can submit their Marketing Authorisation Applications in the form of a rolling submissions and do not need to wait to have a complete data package before submission.
The time taken for MHRA’s review will depend on what data will be submitted and when.
A COVID-19 vaccine will only be deployed once it has been proven to be safe and effective through robust clinical trials and approved for use by the appropriate licensing authority. There are numerous potential vaccine candidates in development, which the United Kingdom will have access to. Once a vaccine is ready, it will be deployed to those most at risk, and then rolled out more widely. Regular testing of virus samples will be undertaken to assess any changes in the virus that may impact on vaccine effectiveness. Safe and effective vaccines rolled out to the population will form part of our overall recovery effort from the impact of this global pandemic.
In terms of the six supply agreements that have and are being negotiated, these cannot be provided at this time due to commercial sensitivity. We are currently also unable to provide information on funding allocated to each potential vaccine for marketing, manufacturing, distribution and administration, as they have not yet been finalised.
There is broad agreement between international regulators on both the safety and the efficacy criteria that would be required for approval and authorisation of a COVID-19 vaccine. These criteria will apply to all COVID-19 vaccine candidates, irrespective of whether they receive funding from the United Kingdom Government.
The Medicines and Healthcare products Regulatory Agency (MHRA) will perform the assessment of the quality, safety and efficacy data submitted by developers of COVID-19 vaccines and will seek the advice of its independent expert advisors on the Commission on Human Medicines.
No approval will be given for any COVID-19 vaccine without robust evidence of efficacy and safety. The MHRA has teams of assessors available to review the submissions.
To expedite the review of COVID-19 vaccine applications, developers of COVID-19 vaccines can submit their Marketing Authorisation Applications in the form of a rolling submissions and do not need to wait to have a complete data package before submission.
The time taken for MHRA’s review will depend on what data will be submitted and when.
We believe there are many potential merits of using frequent rapid antigen tests to help slow the transmission of COVID-19. The use of multiple new testing technologies could significantly improve our detection of positive cases, so that people can isolate themselves and prevent the spread of the disease. As part of the first deployment of whole city testing, residents and workers in Liverpool will for example be tested using a combination of existing swab tests, as well as new lateral flow tests which can rapidly turn around results within an hour without the need to be processed in a lab, as well as LAMP technology due to be deployed in Liverpool University Hospitals NHS Foundation Trust for National Health Service staff.
We have also started a number of pilots across schools, universities and workplaces to assess the use of rapid lateral flow antigen tests. This is in addition to ongoing pilots in Liverpool, Southampton and Salford using the LAMP no-swab saliva test and LAMP asymptomatic testing for NHS staff.
Data or clinical study reports from clinical trials of new medicines are not published before authorisation or prior to trial completion due to commercial confidentiality and concern that publication may influence or bias the on-going trial. The Medicines and Healthcare products Regulatory Agency (MHRA) performs a thorough and robust assessment of clinical trial data together with non-clinical data and manufacturing and control data submitted as part of a Marketing Authorisation Application.
We do not publish data in the format requested.
We do not publish data in the format requested.
The people tested measure for United Kingdom statistics was initially used to avoid counting one person tested several times in a short space of time.
Many people are now retested multiple times for valid reasons, such as regular testing of health and care workers over several months. This means that the ‘tests processed’ figure, which we have published since 4 July 2020, is a better measure of the scale of the testing service.
The polymerase chain reaction (PCR) test is designed to detect viral RNA. Therefore, there will be cases where the PCR test is detecting remnants of viral RNA in the absence of infectious virus.
Public Health England (PHE) has not assessed the extent to which the PCR will pick up viral remnants rather than infectious virus.
An assessment of which positive cases do not reflect contagious virus would depend on individual case by case review. PHE has not performed such a review and therefore does not hold this data.
Public Health England (PHE) does not publish data on COVID-19 cases in higher education settings in the format requested.
PHE publishes incidence data for educational aged cohorts at the following link:
In week 43, there were 311 confirmed COVID-19 clusters or outbreaks in educational settings. Further information can be found at the following link:
https://www.gov.uk/government/statistics/national-flu-and-covid-19-surveillance-reports
We do not publish the information requested. However, all organisations performing tests are aware that they should follow the industry best practice for pathology testing and ensure they meet all the legal and regulatory obligations required for testing for COVID-19.
Under the Health Protection (Notification) Regulations 2010, it is a legal requirement to report positive cases of COVID-19 to Public Health England.
Current United Kingdom guidance is that testing should be undertaken for people who have a new onset of symptoms, and official advice is to get a test as soon as possible after the onset of symptoms. Data related to the time that a swab test is undertaken relative to the time of infection or the time of symptom onset is not routinely collected. Further information on testing is available at the following link:
https://www.gov.uk/guidance/coronavirus-covid-19-getting-tested
The proportion of the population that are infected with the COVID-19 virus is measured through a number of surveillance studies including the COVID-19 Infection Survey (CIS) and the REACT-1 real-time assessment of community transmission of coronavirus study. Both studies provide an estimate of people with COVID-19 infection in the community at a given time – those with symptoms and those without.
Estimates of the population in England that were infected with the COVID-19 virus in October 2020 are as follows:
- CIS - 1.42% (25 October to 31 October); and
- REACT-1 1.28% (16 October – 25 October)
We do not publish data in the format requested.
In June 2020 the Scientific Advisory Group for Emergencies published a briefing paper on the impact of false positives and false negatives in the United Kingdom’s COVID-19 reverse transcription polymerase chain reaction testing programme, which is available at the following link:
https://www.gov.uk/government/publications/gos-impact-of-false-positives-and-negatives-3-june-2020
The briefing paper states that the UK operational false positive rate is unknown.
Health Education England published a draft workforce strategy last week, which emphasised clearly the priority we have to increase the nursing workforce and broaden routes into nursing.
That is why, in England, we have developed the new nursing associate role and Nursing Degree Apprenticeship to open routes into the registered nursing profession for thousands of people from all backgrounds, and allow employers to grow their own workforce from within their local communities.
The UK has a long tradition of collaborative working with European partners on joint defence programmes and maintains regular dialogue with European Union member states, including Italy, to discuss existing and future cooperative programmes. All EU nations are subject to EU procurement directives, which helps maintain a culture of open, transparent and fair competition on public procurement projects. Open competitive markets and more efficient cross-border cooperation are key methods of sustaining our defence industrial capabilities against a backdrop of wider economic instability.
The Ministry of Defence is the lead department for defence industrial relations and, as such, has engaged in detail on these specific areas. The Secretary of State for Foreign and Commonwealth Affairs, my right hon.Friend the Member for Runnymede and Weybridge and I also regularly discuss defence industry matters with European partners, most recently at the May 2015 Foreign Affairs Council, as part of wider defence discussions held at the June 2015 European Council. Our aim is to encourage a globally competitive European defence industry that delivers the capabilities our armed forces need at best value for money, whilst responding to an increasingly diverse range of threats and supporting wider economic growth.
The Prime Minister, my right hon. Friend the Member for Witney (Mr Cameron), the Chancellor of the Exchequer, my right hon. Friend the Member for Tatton (Mr Osborne), the Secretary of State for Foreign and Commonwealth Affairs, my right hon. Friend the Member for Runnymede and Weybridge (Mr Hammond) and I are focussed on successfully reforming and renegotiating our relationship with the EU. The June European Council saw the successful launch of a process of technical discussions on EU reform. Leaders have agreed to return to the issue at the December European Council.
The Government’s preferred approach to customs, the facilitated customs arrangement (FCA), would avoid any need for customs declarations on cross-border trade and would ensure there are no stops or checks at the land border. The FCA will therefore fully deliver on the Government’s commitments to avoid a hard land border.
The UK is also seeking to be at the cutting edge of global customs policy. As the Government outlined in the “future customs arrangements” paper in August 2017, it has been exploring possible ways in which to use future advancements in technology to streamline the trading process; including by simplifying existing procedures to reduce burdens on business, or speeding up some authorisation processes through increased automation. The UK will look to implement such innovations, bilaterally or unilaterally, to promote the greatest possible trade with the rest of the world.
The deadline for responses to the business rates review was 12 June 2015. We have been undertaking analysis and considering the wide variety of views put forward in stakeholder responses.
The Summer Budget confirmed that the review will be fiscally neutral and will conclude by the end of the year.
We plan to retain Puma in service until at least 2025. Work to investigate delivery of this capability beyond the mid-2020s is under way but it would be premature to provide a formal decision date.
The UK has a long tradition of collaborative working with European partners on joint defence programmes and maintains regular dialogue with European Union member states, including Italy, to discuss existing and future cooperative programmes. All EU nations are subject to EU procurement directives, which ensures a culture of open, transparent and fair competition is maintained on public procurement projects. Open competitive markets and more efficient cross-border cooperation are key methods of sustaining our defence industrial capabilities against a backdrop of wider economic instability.
We regularly review the financial and business robustness of our supply chain, covering both UK-based and foreign-owned suppliers. Any risks or concerns are addressed as part of normal commercial activity and through regular meetings with our suppliers.
The Chancellor has announced a review of business rates. The Government is currently considering responses to the review’s call for evidence and has committed to publish a response in Spring 2021. Businesses in the retail, hospitality and leisure sectors have benefitted from rates reliefs worth approximately £10 billion in the current financial year.
Mediation for family law cases is already available under Part I of the Legal Aid, Sentencing and Punishment of Offenders Act 2012 (LASPO).
The department recently conducted an extensive review of LASPO and has announced several changes as part of the Legal Support Action Plan. These included expanding the scope of legal aid in family law to cover representation for special guardianship orders and placement orders.
Data is not held on successful cases, but the Legal Aid Agency does hold data on cases that have started (and are funded by legal aid). These statistics are included below for both family law mediation and immigration cases for the last three years:
Legal aid in cases involving family law mediation |
| |||||||||||||||||||||||
Financial Year | Family Mediation | |||||||||||||||||||||||
2016-17 | 7,611 | |||||||||||||||||||||||
2017-18 | 6,302 | |||||||||||||||||||||||
2018-19 | 6,515 | |||||||||||||||||||||||
Note: ‘Proportion started’ data is not held for family mediation matters, as the application process and decision on whether to grant funding is devolved to the solicitor in question (the provider). |
|
Legal aid in cases involving Immigration |
| |||||||||||||||||||||
| ||||||||||||||||||||||
Legal help | Civil representation | |||||||||||||||||||||
Financial Year | Grants | Applications | Grants | Proportion granted |
| |||||||||||||||||
2016-17 | 29,111 | 1,904 | 1,404 | 74% |
| |||||||||||||||||
2017-18 | 26,609 | 1,596 | 1,203 | 75% |
| |||||||||||||||||
2018-19 | 28,821 | 1,535 | 1,155 | 75% |
| |||||||||||||||||
| ||||||||||||||||||||||
Legal help is assistance short of representation. Note: ‘Proportion granted’ data is not held for Legal Help matters, as the application process and decision on whether to grant funding is devolved to the solicitor in question (the provider). |
|
Mediation for family law cases is already available under Part I of the Legal Aid, Sentencing and Punishment of Offenders Act 2012 (LASPO).
The department recently conducted an extensive review of LASPO and has announced several changes as part of the Legal Support Action Plan. These included expanding the scope of legal aid in family law to cover representation for special guardianship orders and placement orders.
Data is not held on successful cases, but the Legal Aid Agency does hold data on cases that have started (and are funded by legal aid). These statistics are included below for both family law mediation and immigration cases for the last three years:
Legal aid in cases involving family law mediation |
| |||||||||||||||||||||||
Financial Year | Family Mediation | |||||||||||||||||||||||
2016-17 | 7,611 | |||||||||||||||||||||||
2017-18 | 6,302 | |||||||||||||||||||||||
2018-19 | 6,515 | |||||||||||||||||||||||
Note: ‘Proportion started’ data is not held for family mediation matters, as the application process and decision on whether to grant funding is devolved to the solicitor in question (the provider). |
|
Legal aid in cases involving Immigration |
| |||||||||||||||||||||
| ||||||||||||||||||||||
Legal help | Civil representation | |||||||||||||||||||||
Financial Year | Grants | Applications | Grants | Proportion granted |
| |||||||||||||||||
2016-17 | 29,111 | 1,904 | 1,404 | 74% |
| |||||||||||||||||
2017-18 | 26,609 | 1,596 | 1,203 | 75% |
| |||||||||||||||||
2018-19 | 28,821 | 1,535 | 1,155 | 75% |
| |||||||||||||||||
| ||||||||||||||||||||||
Legal help is assistance short of representation. Note: ‘Proportion granted’ data is not held for Legal Help matters, as the application process and decision on whether to grant funding is devolved to the solicitor in question (the provider). |
|